Lifileucel

{
  "id": "MLC-T-ONC-004831",
  "term": "Lifileucel",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A treatment used for adults with melanoma that has spread to other parts of the body or cannot be removed by surgery. It is used in patients whose cancer did not get better after treatment with an antibody that blocks PD-1 (and treatment with a BRAF inhibitor, for those with a BRAF mutation). It is also being studied in the treatment of other types of cancer. Lifileucel is made using tumor-infiltrating lymphocytes (a type of immune cell that can recognize and kill tumor cells) from a patient’s tumor. These lymphocytes are tested in the laboratory to find out which ones best recognize the tumor cells. The selected lymphocytes are then grown in large numbers in the laboratory and given back to the patient to help the immune system kill the tumor cells. Lifileucel is a type of cellular immunotherapy called tumor-infiltrating lymphocyte therapy. Also called Amtagvi.",
    "A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro."
  ],
  "synonyms": [
    "Amtagvi",
    "autologous TIL LN-144",
    "Contego",
    "autologous tumor infiltrating lymphocytes LN-144"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lifileucel/"
}